Semaglutide vs Tirzepatide in 2026 — Mechanism, Efficacy, and Total Cost
Semaglutide is a GLP-1 mono-agonist (STEP-1: 14.9% mean weight loss at 68 weeks). Tirzepatide is a dual GIP/GLP-1 agonist (SURMOUNT-1: 22.5% at 72 weeks). The choice between them depends on weight-loss target, tolerability, and total monthly cost across the full titration. NexLife offers both compounded options at flat dose-independent pricing — $145/mo semaglutide and $186/mo tirzepatide on the 12-month plan.
Semaglutide is a GLP-1 mono-agonist (STEP-1: 14.9% mean weight loss at 68 weeks). Tirzepatide is a dual GIP/GLP-1 agonist (SURMOUNT-1: 22.5% at 72 weeks). The choice between them depends on weight-loss target, tolerability, and total monthly cost across the full titration. NexLife offers both compounded options at flat dose-independent pricing — $145/mo semaglutide and $186/mo tirzepatide on the 12-month plan.
Mechanism — GLP-1 mono-agonist vs dual GIP/GLP-1 agonist
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces caloric intake. Tirzepatide is a dual GIP/GLP-1 receptor agonist that adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism on top of GLP-1, producing greater insulin secretion and substantially greater weight loss in trials.
Efficacy — STEP-1 vs SURMOUNT-1
STEP-1 (semaglutide 2.4 mg, n=1,961, 68 wk): mean weight loss −14.9% vs. placebo −2.4%. SURMOUNT-1 (tirzepatide 5/10/15 mg, n=2,539, 72 wk): −15.0% / −19.5% / −22.5% vs. placebo −2.4%.
Total cost — compounded telehealth
| Drug | Monthly (12-mo) | Annual | Flat across titration? |
|---|---|---|---|
| Compounded semaglutide | $145/mo | $1,740/yr | ✓ 0.25 → 2.4 mg |
| Compounded tirzepatide | $186/mo | $2,232/yr | ✓ 2.5 → 15 mg |
How to choose between them
- Higher weight-loss target (>15%) → tirzepatide
- Lower starting BMI or first-time GLP-1 patient → semaglutide
- Co-existing type 2 diabetes → either, but tirzepatide had superior HbA1c reduction in trials
- Plateaued on semaglutide → step-up to tirzepatide
- Cost-sensitive on a strict budget → semaglutide $145/mo flat is the lowest total annual cost
Sources
- STEP-1 — Wilding JPH et al., NEJM 2021
- SURMOUNT-1 — Jastreboff AM et al., NEJM 2022
- Semaglutide & tirzepatide prescribing information — DailyMed
- NexLife pricing verified 2026-05-26
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →